A clinical, pathological and immunohistochemical series of 9 cases of primary cutaneous apocrine carcinomas of the head and neck.
cutaneous apocrine carcinoma
head and neck
hormone receptors
metastatic breast cancer
skin metastasis
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
13
07
2019
accepted:
20
10
2019
pubmed:
19
11
2019
medline:
16
3
2021
entrez:
19
11
2019
Statut:
ppublish
Résumé
Primary cutaneous apocrine carcinoma is a rare malignant adnexal skin tumour that can recur locally, spread to regional lymph nodes and metastatize to visceral organs. Wide dissemination and death from disease are much less common. The axilla is the most common site of presentation. It is infrequently reported in the head and neck region. All cases diagnosed as primary cutaneous apocrine carcinoma of the head and neck were retrospectively collected from the archives of the Division of Pathological Anatomy, University of Florence from 1996 to 2016. There was no history or clinical evidence of breast cancer. Clinical data and follow-up were collected by the clinicians. Nine cases were found, with a mean age of 76 years, ranging in size between 0.3 and 3.5 cm. Clinically, they were frequently mistaken for basal cell carcinomas. Histopathologically, all the tumours showed decapitation secretion, a tubular, solid or mixed (tubulo-papillary and solid-tubular) growth pattern and were predominantly classified as grade 2 tumours. GCDFP-15 and hormone receptors were variably expressed. HER2 and podoplanin were negative in all cases. In one case, spreading to regional lymph nodes was observed. No cases were associated with death due to the disease. As immunohistochemical analysis lacks specificity in distinguishing primary cutaneous apocrine carcinoma from a cutaneous metastasis of breast carcinoma, detailed clinical history, breast examination, adequate treatment and follow-up are necessary to confirm a diagnosis of primary cutaneous apocrine carcinoma.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Primary cutaneous apocrine carcinoma is a rare malignant adnexal skin tumour that can recur locally, spread to regional lymph nodes and metastatize to visceral organs. Wide dissemination and death from disease are much less common. The axilla is the most common site of presentation. It is infrequently reported in the head and neck region.
METHODS
METHODS
All cases diagnosed as primary cutaneous apocrine carcinoma of the head and neck were retrospectively collected from the archives of the Division of Pathological Anatomy, University of Florence from 1996 to 2016. There was no history or clinical evidence of breast cancer. Clinical data and follow-up were collected by the clinicians.
RESULTS
RESULTS
Nine cases were found, with a mean age of 76 years, ranging in size between 0.3 and 3.5 cm. Clinically, they were frequently mistaken for basal cell carcinomas. Histopathologically, all the tumours showed decapitation secretion, a tubular, solid or mixed (tubulo-papillary and solid-tubular) growth pattern and were predominantly classified as grade 2 tumours. GCDFP-15 and hormone receptors were variably expressed. HER2 and podoplanin were negative in all cases. In one case, spreading to regional lymph nodes was observed. No cases were associated with death due to the disease.
CONCLUSION
CONCLUSIONS
As immunohistochemical analysis lacks specificity in distinguishing primary cutaneous apocrine carcinoma from a cutaneous metastasis of breast carcinoma, detailed clinical history, breast examination, adequate treatment and follow-up are necessary to confirm a diagnosis of primary cutaneous apocrine carcinoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e189-e195Informations de copyright
© 2019 The Australasian College of Dermatologists.
Références
Robson A, Lazar AJ, Ben Nagi J et al. Primary Cutaneous Apocrine Carcinoma: A Clinico-pathologic Analysis of 24 Cases. Am. J. Surg. Pathol. 2008; 32: 682-90.
Hollowell KL, Agle SC, Zervos EE et al. Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. J. Surg. Oncol. 2012; 105: 415-19.
Stam H, Lohuis PJ, Zupan-Kajcovski B et al. Increasing incidence and survival of a rare skin cancer in the Netherlands. A population-based study of 2,220 cases of skin adnexal carcinoma. J. Surg. Oncol. 2013; 107: 822-27.
Ogata D, Kiyohara Y, Yoshikawa S et al. Treatment strategy for cutaneous apocrine carcinoma. Int. J. Clin. Oncol. 2014; 19: 712-15.
Hibler BP, Barker CA, Hollmann TJ et al. Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation. JAAD Case Rep. 2017; 3: 259-62.
Danialan R, Mutyambizi K, Aung P et al. Challenges in the diagnosis of cutaneous adnexal tumours. J. Clin. Pathol. 2015; 68: 992-1002.
Mentrikoski MJ, Wick MR. Immunohistochemical distinction of primary sweat gland carcinoma and metastatic breast carcinoma: can it always be accomplished reliably? Am J Clin Pathol 2015; 143: 430-36.
Fernandez-Flores A. A modern approach to differential diagnosis between cutaneous apocrine carcinoma and metastasis from breast carcinoma. Am. J. Dermatopathol. 2016; 38: 162-64.
Cardoso JC, Calonje E. Malignant sweat gland tumours: an update. Histopathology 2015; 67: 589-606.
Elder DE, Massi D, Scolyer RA et al. WHO Classification of Skin Tumours, 4th edn. Lyon: IARC, 2018.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
Warkel RL, Helwig EB. Apocrine gland adenoma and adenocarcinoma of the axilla. Arch. Dermatol. 1978; 114: 198-203.
Zelger B, Kazakov DV, Zelger BG. Klinik der Hautadnextumoren [Clinical presentation of cutaneous adnexal tumors]. Pathologe 2014; 35: 487-96.
Cham PM, Niehans GA, Foman N et al. Primary cutaneous apocrine carcinoma presenting as carcinoma erysipeloides. Br. J. Dermatol 2008; 158: 194-96.
Farkaš R. Apocrine secretion: New insights into an old phenomenon. Biochim Biophys Acta 2015; 1850: 1740-50.
Tlemcani K, Levine D, Smith RV et al. Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy. J. Clin. Oncol. 2010; 28: e412-14.
Shimato S, Wakabayashi T, Mizuno M et al. Brain metastases from apocrine carcinoma of the scalp: case report. J. Neurooncol. 2006; 77: 285-89.
Le LP, Dias-Santagata D, Pawlak AC et al. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS ONE 2012; 7: e47290.
Piris A, Peng Y, Boussahmain C et al. Cutaneous and mammary apocrine carcinomas have different immunoprofiles. Hum. Pathol. 2014; 45: 320-26
Weinreb I, Bergfeld WF, Patel RM et al. Apocrine carcinoma in situ of sweat duct origin. Am. J. Surg. Pathol. 2009; 33: 155-7.
Tsutsumi Y. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn. J. Clin. Oncol. 2012; 42: 375-86.
Mills AM, Gottlieb E, M. Wendroth S et al. Pure Apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers. Am. J. Surg. Pathol. 2016; 40: 1109-16.
Desman GT, Ozerdem U, Shin SJ. Neighboring look-a-likes: distinguishing between breast and dermatologic lesions. Adv. Anat. Pathol. 2014; 21: 228-47.
Toledo-Pastrana T, Llombart-Cussac B, Traves-Zapata V et al. Case report: differential diagnosis between primary cutaneous apocrine adenocarcinoma versus extramammary or metastatic breast adenocarcinoma. Am. J. Dermatopathol. 2014; 36: e175-8.
Schulman JM, Pauli ML, Neuhaus IM et al. The distribution of cutaneous metastases correlates with local immunologic milieu. J. Am. Acad. Dermatol. 2016; 74: 470-76.
De Giorgi V, Grazzini M, Alfaioli B et al. Cutaneous manifestations of breast carcinoma. Dermatol. Ther. 2010; 23: 581-89.
Otsuka M, Yamasaki O, Kaji T et al. Metastatic cutaneous apocrine adenocarcinoma treated with a combination of Pertuzumab-based targeted therapy and Taxane chemotherapy: A case report. JAMA Dermatol. 2016; 152: 111-13.
Furudate S, Fujimura T, Tsukada A et al. Successful treatment of advanced primary cutaneous apocrine carcinoma on the scrotum with systemic chemotherapy and radiotherapy followed by denosumab. Case Rep. Oncol. 2017; 10: 52-56.
Fujisawa Y, Fujimoto M. Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine. J. Dermatol. 2014; 41: 280-82.
Hidaka T, Fujimura T, Watabe A et al. Successful treatment of HER- 2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine. Acta Derm. Venereol. 2012; 92: 654-55.